We are excited to announce that Cambridge Bioscience has partnered with Micronbrane Medical, a leader in providing innovative solutions for metagenomic next generation sequencing (mNGS).
Micronbrane Medical is at the forefront of mNGS by providing fast, accurate detection of known and novel microorganisms while minimising contamination throughout the process. Committed to overcoming cost and technical challenges, the company has developed PaRTI-Seq, a comprehensive assay, and PaRTI-Cular, a bioinformatics platform. These innovations make mNGS accessible, cost-effective, and practical for global health applications, positioning it as a vital tool for diagnosing and treating infectious diseases.
Cambridge Bioscience will distribute Micronbane products in the UK and Ireland.
Learn more about Micronbrane or contact our Micronbrane specialists